Thyroid eye disease (TED) produces chronic orbital inflammation that may result in restrictive extraocular myopathy and associated diplopia. TED-related strabismus can be challenging to address due to complex and often large-angle deviations, variable surgical results, high rates of reoperation, and profound impact on patients' function and quality of life. We address the evaluation and management of strabismus in TED, and discuss changes that the recent introduction of teprotumumab may have on timing and treatment options previously chosen.
Shi et al. (Mon,) studied this question.